ID   XRCC1_HUMAN             Reviewed;         633 AA.
AC   P18887; Q6IBS4; Q9HCB1;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 2.
DT   07-APR-2021, entry version 217.
DE   RecName: Full=DNA repair protein XRCC1;
DE   AltName: Full=X-ray repair cross-complementing protein 1;
GN   Name=XRCC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT TYR-576.
RX   PubMed=2247054; DOI=10.1128/mcb.10.12.6160;
RA   Thompson L.H., Brookman K.W., Jones N.J., Allen S.A., Carrano A.V.;
RT   "Molecular cloning of the human XRCC1 gene, which corrects defective DNA
RT   strand break repair and sister chromatid exchange.";
RL   Mol. Cell. Biol. 10:6160-6171(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ALA-72; LEU-161; TRP-194;
RP   HIS-280; ALA-304; SER-309; GLN-399 AND SER-576.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS GLN-399 AND TYR-576.
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLN-399.
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS GLN-399 AND TYR-576.
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION.
RX   PubMed=11163244; DOI=10.1016/s0092-8674(01)00195-7;
RA   Whitehouse C.J., Taylor R.M., Thistlethwaite A., Zhang H.,
RA   Karimi-Busheri F., Lasko D.D., Weinfeld M., Caldecott K.W.;
RT   "XRCC1 stimulates human polynucleotide kinase activity at damaged DNA
RT   termini and accelerates DNA single-strand break repair.";
RL   Cell 104:107-117(2001).
RN   [7]
RP   INTERACTION WITH APTX.
RX   PubMed=14755728; DOI=10.1002/ana.10808;
RA   Sano Y., Date H., Igarashi S., Onodera O., Oyake M., Takahashi T.,
RA   Hayashi S., Morimatsu M., Takahashi H., Makifuchi T., Fukuhara N.,
RA   Tsuji S.;
RT   "Aprataxin, the causative protein for EAOH is a nuclear protein with a
RT   potential role as a DNA repair protein.";
RL   Ann. Neurol. 55:241-249(2004).
RN   [8]
RP   PHOSPHORYLATION AT SER-485 AND THR-488, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=15066279; DOI=10.1016/s0092-8674(04)00206-5;
RA   Loizou J.I., El-Khamisy S.F., Zlatanou A., Moore D.J., Chan D.W., Qin J.,
RA   Sarno S., Meggio F., Pinna L.A., Caldecott K.W.;
RT   "The protein kinase CK2 facilitates repair of chromosomal DNA single-strand
RT   breaks.";
RL   Cell 117:17-28(2004).
RN   [9]
RP   INTERACTION WITH APTX, AND PHOSPHORYLATION.
RX   PubMed=15380105; DOI=10.1016/j.dnarep.2004.06.017;
RA   Clements P.M., Breslin C., Deeks E.D., Byrd P.J., Ju L., Bieganowski P.,
RA   Brenner C., Moreira M.-C., Taylor A.M.R., Caldecott K.W.;
RT   "The ataxia-oculomotor apraxia 1 gene product has a role distinct from ATM
RT   and interacts with the DNA strand break repair proteins XRCC1 and XRCC4.";
RL   DNA Repair 3:1493-1502(2004).
RN   [10]
RP   INTERACTION WITH APTX.
RX   PubMed=15044383; DOI=10.1093/hmg/ddh122;
RA   Gueven N., Becherel O.J., Kijas A.W., Chen P., Howe O., Rudolph J.H.,
RA   Gatti R., Date H., Onodera O., Taucher-Scholz G., Lavin M.F.;
RT   "Aprataxin, a novel protein that protects against genotoxic stress.";
RL   Hum. Mol. Genet. 13:1081-1093(2004).
RN   [11]
RP   SUMOYLATION.
RX   PubMed=15561718; DOI=10.1074/jbc.m411718200;
RA   Gocke C.B., Yu H., Kang J.;
RT   "Systematic identification and analysis of mammalian small ubiquitin-like
RT   modifier substrates.";
RL   J. Biol. Chem. 280:5004-5012(2005).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-421, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [13]
RP   SUBUNIT, AND PHOSPHORYLATION AT SER-371.
RX   PubMed=16397295; DOI=10.1093/nar/gkj409;
RA   Levy N., Martz A., Bresson A., Spenlehauer C., de Murcia G.,
RA   Menissier-de Murcia J.;
RT   "XRCC1 is phosphorylated by DNA-dependent protein kinase in response to DNA
RT   damage.";
RL   Nucleic Acids Res. 34:32-41(2006).
RN   [14]
RP   INTERACTION WITH APLF.
RX   PubMed=17507382; DOI=10.1074/jbc.c700060200;
RA   Bekker-Jensen S., Fugger K., Danielsen J.R., Gromova I., Sehested M.,
RA   Celis J., Bartek J., Lukas J., Mailand N.;
RT   "Human Xip1 (C2orf13) is a novel regulator of cellular responses to DNA
RT   strand breaks.";
RL   J. Biol. Chem. 282:19638-19643(2007).
RN   [15]
RP   INTERACTION WITH APLF, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=17353262; DOI=10.1128/mcb.02269-06;
RA   Iles N., Rulten S., El-Khamisy S.F., Caldecott K.W.;
RT   "APLF (C2orf13) is a novel human protein involved in the cellular response
RT   to chromosomal DNA strand breaks.";
RL   Mol. Cell. Biol. 27:3793-3803(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226; SER-241; THR-257;
RP   SER-259; SER-408; SER-409; SER-410 AND THR-453, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-198; SER-199; SER-226;
RP   SER-241; THR-453; SER-461; SER-485 AND THR-488, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   INTERACTION WITH APEX1.
RX   PubMed=19934257; DOI=10.1093/nar/gkp1039;
RA   Yamamori T., DeRicco J., Naqvi A., Hoffman T.A., Mattagajasingh I.,
RA   Kasuno K., Jung S.B., Kim C.S., Irani K.;
RT   "SIRT1 deacetylates APE1 and regulates cellular base excision repair.";
RL   Nucleic Acids Res. 38:832-845(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-140; THR-202; SER-204;
RP   SER-241 AND THR-257, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241; THR-453 AND THR-457, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226; SER-241; SER-266;
RP   THR-281; SER-447; THR-453 AND THR-457, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-446; SER-447; THR-453;
RP   THR-457 AND SER-461, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-176, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [25]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-176, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [26]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-176, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-176, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [28]
RP   STRUCTURE BY NMR OF 306-422.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first BRCT domain of DNA-repair protein XRCC1.";
RL   Submitted (JUN-2006) to the PDB data bank.
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 515-522 IN COMPLEX WITH PNKP, AND
RP   PHOSPHORYLATION AT SER-518; THR-519 AND THR-523.
RX   PubMed=19155274; DOI=10.1093/nar/gkn1086;
RA   Ali A.A., Jukes R.M., Pearl L.H., Oliver A.W.;
RT   "Specific recognition of a multiply phosphorylated motif in the DNA repair
RT   scaffold XRCC1 by the FHA domain of human PNK.";
RL   Nucleic Acids Res. 37:1701-1712(2009).
RN   [30]
RP   VARIANTS TRP-194; HIS-280 AND GLN-399.
RX   PubMed=9485007;
RA   Shen M.R., Jones I.M., Mohrenweiser H.;
RT   "Nonconservative amino acid substitution variants exist at polymorphic
RT   frequency in DNA repair genes in healthy humans.";
RL   Cancer Res. 58:604-608(1998).
RN   [31]
RP   VARIANT GLN-399.
RX   PubMed=10783319; DOI=10.1093/carcin/21.5.965;
RA   Duell E.J., Wiencke J.K., Cheng T.J., Varkonyi A., Zuo Z.F., Ashok T.D.,
RA   Mark E.J., Wain J.C., Christiani D.C., Kelsey K.T.;
RT   "Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of
RT   DNA damage in human blood mononuclear cells.";
RL   Carcinogenesis 21:965-971(2000).
RN   [32]
RP   VARIANT GLN-399.
RX   PubMed=11782372;
RA   Nelson H.H., Kelsey K.T., Mott L.A., Karagas M.R.;
RT   "The XRCC1 Arg399Gln polymorphism, sunburn, and non-melanoma skin cancer:
RT   evidence of gene-environment interaction.";
RL   Cancer Res. 62:152-155(2002).
RN   [33]
RP   VARIANT [LARGE SCALE ANALYSIS] TRP-350.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [34]
RP   INVOLVEMENT IN SCAR26, VARIANTS SCAR26 ASN-431 AND 465-GLN--ALA-633 DEL,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=28002403; DOI=10.1038/nature20790;
RG   Care4Rare Canada Consortium;
RA   Hoch N.C., Hanzlikova H., Rulten S.L., Tetreault M., Komulainen E., Ju L.,
RA   Hornyak P., Zeng Z., Gittens W., Rey S.A., Staras K., Mancini G.M.,
RA   McKinnon P.J., Wang Z.Q., Wagner J.D., Yoon G., Caldecott K.W.;
RT   "XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar
RT   ataxia.";
RL   Nature 541:87-91(2017).
RN   [35]
RP   VARIANT [LARGE SCALE ANALYSIS] TYR-576, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Involved in DNA single-strand break repair by mediating the
CC       assembly of DNA break repair protein complexes. Probably during DNA
CC       repair, negatively regulates ADP-ribose levels by modulating ADP-
CC       ribosyltransferase PARP1 activity. {ECO:0000269|PubMed:28002403}.
CC   -!- SUBUNIT: Homodimer. Interacts with polynucleotide kinase (PNK), DNA
CC       polymerase-beta (POLB) and DNA ligase III (LIG3). Interacts with APTX
CC       and APLF. Interacts with APEX1; the interaction is induced by SIRT1 and
CC       increases with the acetylated form of APEX1.
CC       {ECO:0000269|PubMed:11163244, ECO:0000269|PubMed:14755728,
CC       ECO:0000269|PubMed:15044383, ECO:0000269|PubMed:15380105,
CC       ECO:0000269|PubMed:16397295, ECO:0000269|PubMed:17353262,
CC       ECO:0000269|PubMed:17507382, ECO:0000269|PubMed:19155274,
CC       ECO:0000269|PubMed:19934257}.
CC   -!- INTERACTION:
CC       P18887; Q8IW19: APLF; NbExp=11; IntAct=EBI-947466, EBI-1256044;
CC       P18887; Q7Z2E3: APTX; NbExp=11; IntAct=EBI-947466, EBI-847814;
CC       P18887; O96017: CHEK2; NbExp=8; IntAct=EBI-947466, EBI-1180783;
CC       P18887; P61244: MAX; NbExp=2; IntAct=EBI-947466, EBI-751711;
CC       P18887; P09874: PARP1; NbExp=6; IntAct=EBI-947466, EBI-355676;
CC       P18887; Q96T60: PNKP; NbExp=6; IntAct=EBI-947466, EBI-1045072;
CC       P18887; P06746: POLB; NbExp=3; IntAct=EBI-947466, EBI-713836;
CC       P18887; Q9UNA4: POLI; NbExp=2; IntAct=EBI-947466, EBI-741774;
CC       P18887; Q9NUW8: TDP1; NbExp=2; IntAct=EBI-947466, EBI-2902553;
CC       P18887; P06766: Polb; Xeno; NbExp=4; IntAct=EBI-947466, EBI-15845002;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17353262,
CC       ECO:0000269|PubMed:28002403}. Note=Moves from the nucleoli to the
CC       global nuclear chromatin upon DNA damage.
CC       {ECO:0000269|PubMed:28002403}.
CC   -!- TISSUE SPECIFICITY: Expressed in fibroblasts, retinal pigmented
CC       epithelial cells and lymphoblastoid cells (at protein level).
CC       {ECO:0000269|PubMed:28002403}.
CC   -!- PTM: Phosphorylation of Ser-371 causes dimer dissociation.
CC       Phosphorylation by CK2 promotes interaction with APTX and APLF.
CC       {ECO:0000269|PubMed:15066279, ECO:0000269|PubMed:15380105,
CC       ECO:0000269|PubMed:16397295, ECO:0000269|PubMed:17353262,
CC       ECO:0000269|PubMed:19155274}.
CC   -!- PTM: Sumoylated. {ECO:0000269|PubMed:15561718}.
CC   -!- POLYMORPHISM: Carriers of the polymorphic Gln-399 allele may be at
CC       greater risk for tobacco- and age-related DNA damage.
CC   -!- DISEASE: Spinocerebellar ataxia, autosomal recessive, 26 (SCAR26)
CC       [MIM:617633]: A form of spinocerebellar ataxia, a clinically and
CC       genetically heterogeneous group of cerebellar disorders due to
CC       degeneration of the cerebellum with variable involvement of the
CC       brainstem and spinal cord. SCAR26 is a progressive disease
CC       characterized by gait and limb ataxia, loss of independent ambulation,
CC       oculomotor apraxia, and peripheral neuropathy with distal muscle
CC       weakness and areflexia. {ECO:0000269|PubMed:28002403}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/xrcc1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M36089; AAA63270.1; -; mRNA.
DR   EMBL; AF512504; AAM34791.1; -; Genomic_DNA.
DR   EMBL; CR456728; CAG33009.1; -; mRNA.
DR   EMBL; AC018758; AAG09061.1; -; Genomic_DNA.
DR   EMBL; L34079; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC023593; AAH23593.1; -; mRNA.
DR   CCDS; CCDS12624.1; -.
DR   PIR; A36353; A36353.
DR   RefSeq; NP_006288.2; NM_006297.2.
DR   PDB; 1CDZ; X-ray; 3.20 A; A=538-633.
DR   PDB; 1XNA; NMR; -; A=1-183.
DR   PDB; 1XNT; NMR; -; A=1-183.
DR   PDB; 2D8M; NMR; -; A=305-420.
DR   PDB; 2W3O; X-ray; 1.85 A; C/D=515-522.
DR   PDB; 3K75; X-ray; 2.95 A; B/C=1-183.
DR   PDB; 3K77; X-ray; 2.60 A; A/B/C/D/E/F/G/H=1-155.
DR   PDB; 3LQC; X-ray; 2.35 A; A=1-183.
DR   PDB; 5E6Q; X-ray; 2.31 A; A=241-276.
DR   PDB; 5W7X; X-ray; 2.00 A; E/F/G/H=514-522.
DR   PDB; 5W7Y; X-ray; 2.10 A; C/D=514-521.
DR   PDBsum; 1CDZ; -.
DR   PDBsum; 1XNA; -.
DR   PDBsum; 1XNT; -.
DR   PDBsum; 2D8M; -.
DR   PDBsum; 2W3O; -.
DR   PDBsum; 3K75; -.
DR   PDBsum; 3K77; -.
DR   PDBsum; 3LQC; -.
DR   PDBsum; 5E6Q; -.
DR   PDBsum; 5W7X; -.
DR   PDBsum; 5W7Y; -.
DR   BMRB; P18887; -.
DR   SASBDB; P18887; -.
DR   SMR; P18887; -.
DR   BioGRID; 113349; 104.
DR   CORUM; P18887; -.
DR   DIP; DIP-39067N; -.
DR   IntAct; P18887; 63.
DR   MINT; P18887; -.
DR   STRING; 9606.ENSP00000262887; -.
DR   iPTMnet; P18887; -.
DR   PhosphoSitePlus; P18887; -.
DR   BioMuta; XRCC1; -.
DR   DMDM; 317373290; -.
DR   EPD; P18887; -.
DR   jPOST; P18887; -.
DR   MassIVE; P18887; -.
DR   MaxQB; P18887; -.
DR   PaxDb; P18887; -.
DR   PeptideAtlas; P18887; -.
DR   PRIDE; P18887; -.
DR   ProteomicsDB; 53619; -.
DR   Antibodypedia; 1863; 558 antibodies.
DR   Ensembl; ENST00000262887; ENSP00000262887; ENSG00000073050.
DR   GeneID; 7515; -.
DR   KEGG; hsa:7515; -.
DR   UCSC; uc002owt.3; human.
DR   CTD; 7515; -.
DR   DisGeNET; 7515; -.
DR   GeneCards; XRCC1; -.
DR   HGNC; HGNC:12828; XRCC1.
DR   HPA; ENSG00000073050; Low tissue specificity.
DR   MalaCards; XRCC1; -.
DR   MIM; 194360; gene.
DR   MIM; 617633; phenotype.
DR   neXtProt; NX_P18887; -.
DR   PharmGKB; PA369; -.
DR   VEuPathDB; HostDB:ENSG00000073050.11; -.
DR   eggNOG; KOG3226; Eukaryota.
DR   HOGENOM; CLU_030026_0_0_1; -.
DR   InParanoid; P18887; -.
DR   OrthoDB; 539462at2759; -.
DR   PhylomeDB; P18887; -.
DR   TreeFam; TF101201; -.
DR   PathwayCommons; P18887; -.
DR   Reactome; R-HSA-110381; Resolution of AP sites via the single-nucleotide replacement pathway.
DR   Reactome; R-HSA-5649702; APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway.
DR   Reactome; R-HSA-5685939; HDR through MMEJ (alt-NHEJ).
DR   Reactome; R-HSA-5696397; Gap-filling DNA repair synthesis and ligation in GG-NER.
DR   Reactome; R-HSA-6782210; Gap-filling DNA repair synthesis and ligation in TC-NER.
DR   SignaLink; P18887; -.
DR   SIGNOR; P18887; -.
DR   BioGRID-ORCS; 7515; 105 hits in 1001 CRISPR screens.
DR   ChiTaRS; XRCC1; human.
DR   EvolutionaryTrace; P18887; -.
DR   GeneWiki; XRCC1; -.
DR   GenomeRNAi; 7515; -.
DR   Pharos; P18887; Tbio.
DR   PRO; PR:P18887; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P18887; protein.
DR   Bgee; ENSG00000073050; Expressed in ventricular zone and 232 other tissues.
DR   ExpressionAtlas; P18887; baseline and differential.
DR   Genevisible; P18887; HS.
DR   GO; GO:0000785; C:chromatin; IDA:UniProtKB.
DR   GO; GO:0000781; C:chromosome, telomeric region; IEA:Ensembl.
DR   GO; GO:0070522; C:ERCC4-ERCC1 complex; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:1990599; F:3' overhang single-stranded DNA endodeoxyribonuclease activity; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0032356; F:oxidized DNA binding; IMP:UniProtKB.
DR   GO; GO:0006284; P:base-excision repair; IBA:GO_Central.
DR   GO; GO:0006288; P:base-excision repair, DNA ligation; TAS:Reactome.
DR   GO; GO:0006287; P:base-excision repair, gap-filling; TAS:Reactome.
DR   GO; GO:0021587; P:cerebellum morphogenesis; IEA:Ensembl.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; TAS:Reactome.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IEA:Ensembl.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:1905765; P:negative regulation of protection from non-homologous end joining at telomere; IEA:Ensembl.
DR   GO; GO:0010836; P:negative regulation of protein ADP-ribosylation; IMP:UniProtKB.
DR   GO; GO:0006297; P:nucleotide-excision repair, DNA gap filling; TAS:Reactome.
DR   GO; GO:1904877; P:positive regulation of DNA ligase activity; IMP:UniProtKB.
DR   GO; GO:1903518; P:positive regulation of single strand break repair; IMP:UniProtKB.
DR   GO; GO:1990414; P:replication-born double-strand break repair via sister chromatid exchange; IMP:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0033194; P:response to hydroperoxide; IDA:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0010033; P:response to organic substance; IEA:Ensembl.
DR   GO; GO:0000012; P:single strand break repair; IEA:InterPro.
DR   GO; GO:0061819; P:telomeric DNA-containing double minutes formation; IEA:Ensembl.
DR   GO; GO:0006283; P:transcription-coupled nucleotide-excision repair; TAS:Reactome.
DR   GO; GO:0050882; P:voluntary musculoskeletal movement; IMP:UniProtKB.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 3.40.50.10190; -; 2.
DR   InterPro; IPR001357; BRCT_dom.
DR   InterPro; IPR036420; BRCT_dom_sf.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR002706; Xrcc1_N.
DR   Pfam; PF00533; BRCT; 1.
DR   Pfam; PF16589; BRCT_2; 1.
DR   Pfam; PF01834; XRCC1_N; 1.
DR   SMART; SM00292; BRCT; 2.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF52113; SSF52113; 2.
DR   PROSITE; PS50172; BRCT; 2.
PE   1: Evidence at protein level;
KW   3D-structure; DNA damage; DNA repair; Isopeptide bond; Neurodegeneration;
KW   Nucleus; Phosphoprotein; Reference proteome; Repeat; Ubl conjugation.
FT   CHAIN           1..633
FT                   /note="DNA repair protein XRCC1"
FT                   /id="PRO_0000066044"
FT   DOMAIN          315..403
FT                   /note="BRCT 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   DOMAIN          538..629
FT                   /note="BRCT 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   MOD_RES         140
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         198
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         199
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         202
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         204
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         226
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         241
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         257
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         259
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         266
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         281
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         371
FT                   /note="Phosphoserine; by PRKDC"
FT                   /evidence="ECO:0000269|PubMed:16397295"
FT   MOD_RES         408
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         409
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         410
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         421
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         446
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         447
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         453
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         457
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         461
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         485
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15066279,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         488
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:15066279,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         518
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19155274"
FT   MOD_RES         519
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:19155274"
FT   MOD_RES         523
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:19155274"
FT   CROSSLNK        176
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        176
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   VARIANT         7
FT                   /note="R -> L (in dbSNP:rs2307186)"
FT                   /id="VAR_014773"
FT   VARIANT         10
FT                   /note="V -> M (in dbSNP:rs2307171)"
FT                   /id="VAR_014774"
FT   VARIANT         72
FT                   /note="V -> A (in dbSNP:rs25496)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_016168"
FT   VARIANT         107
FT                   /note="R -> H (in dbSNP:rs2228487)"
FT                   /id="VAR_029228"
FT   VARIANT         157
FT                   /note="E -> K (in dbSNP:rs2307180)"
FT                   /id="VAR_014775"
FT   VARIANT         161
FT                   /note="P -> L (in dbSNP:rs2307191)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_014776"
FT   VARIANT         194
FT                   /note="R -> W (in dbSNP:rs1799782)"
FT                   /evidence="ECO:0000269|PubMed:9485007, ECO:0000269|Ref.2"
FT                   /id="VAR_013400"
FT   VARIANT         280
FT                   /note="R -> H (in dbSNP:rs25489)"
FT                   /evidence="ECO:0000269|PubMed:9485007, ECO:0000269|Ref.2"
FT                   /id="VAR_013401"
FT   VARIANT         298
FT                   /note="K -> N (in dbSNP:rs2307188)"
FT                   /id="VAR_014777"
FT   VARIANT         304
FT                   /note="T -> A (in dbSNP:rs25490)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_018775"
FT   VARIANT         309
FT                   /note="P -> S (in dbSNP:rs25491)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_014778"
FT   VARIANT         350
FT                   /note="R -> W (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs754041352)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036277"
FT   VARIANT         399
FT                   /note="R -> Q (in dbSNP:rs25487)"
FT                   /evidence="ECO:0000269|PubMed:10783319,
FT                   ECO:0000269|PubMed:11782372, ECO:0000269|PubMed:15057824,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:9485007,
FT                   ECO:0000269|Ref.2, ECO:0000269|Ref.3"
FT                   /id="VAR_011487"
FT   VARIANT         431
FT                   /note="K -> N (in SCAR26; may result in aberrant splicing;
FT                   dbSNP:rs761564262)"
FT                   /evidence="ECO:0000269|PubMed:28002403"
FT                   /id="VAR_079140"
FT   VARIANT         465..633
FT                   /note="Missing (in SCAR26)"
FT                   /evidence="ECO:0000269|PubMed:28002403"
FT                   /id="VAR_079141"
FT   VARIANT         485
FT                   /note="S -> Y (in dbSNP:rs2307184)"
FT                   /id="VAR_014779"
FT   VARIANT         514
FT                   /note="P -> L (in dbSNP:rs25474)"
FT                   /id="VAR_016169"
FT   VARIANT         559
FT                   /note="R -> Q (in dbSNP:rs2307167)"
FT                   /id="VAR_014780"
FT   VARIANT         560
FT                   /note="R -> W (in dbSNP:rs2307166)"
FT                   /id="VAR_014781"
FT   VARIANT         576
FT                   /note="N -> S (in dbSNP:rs2307177)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_014782"
FT   VARIANT         576
FT                   /note="N -> Y (in dbSNP:rs2682557)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:2247054, ECO:0000269|Ref.3,
FT                   ECO:0007744|PubMed:21269460"
FT                   /id="VAR_061727"
FT   HELIX           4..6
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   STRAND          7..12
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   HELIX           17..25
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   HELIX           28..36
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   TURN            37..39
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   STRAND          41..53
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   STRAND          57..64
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   STRAND          66..73
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   STRAND          75..77
FT                   /evidence="ECO:0007744|PDB:1XNA"
FT   HELIX           81..83
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   STRAND          85..93
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   HELIX           96..101
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   STRAND          108..111
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   HELIX           113..115
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   HELIX           118..121
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   STRAND          125..133
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   STRAND          138..140
FT                   /evidence="ECO:0007744|PDB:3K75"
FT   STRAND          143..150
FT                   /evidence="ECO:0007744|PDB:3LQC"
FT   HELIX           313..316
FT                   /evidence="ECO:0007744|PDB:2D8M"
FT   TURN            317..319
FT                   /evidence="ECO:0007744|PDB:2D8M"
FT   STRAND          323..329
FT                   /evidence="ECO:0007744|PDB:2D8M"
FT   HELIX           334..344
FT                   /evidence="ECO:0007744|PDB:2D8M"
FT   STRAND          347..352
FT                   /evidence="ECO:0007744|PDB:2D8M"
FT   STRAND          359..366
FT                   /evidence="ECO:0007744|PDB:2D8M"
FT   HELIX           368..376
FT                   /evidence="ECO:0007744|PDB:2D8M"
FT   STRAND          379..382
FT                   /evidence="ECO:0007744|PDB:2D8M"
FT   HELIX           384..391
FT                   /evidence="ECO:0007744|PDB:2D8M"
FT   HELIX           398..401
FT                   /evidence="ECO:0007744|PDB:2D8M"
FT   STRAND          404..407
FT                   /evidence="ECO:0007744|PDB:2D8M"
FT   TURN            542..545
FT                   /evidence="ECO:0007744|PDB:1CDZ"
FT   STRAND          547..550
FT                   /evidence="ECO:0007744|PDB:1CDZ"
FT   HELIX           557..568
FT                   /evidence="ECO:0007744|PDB:1CDZ"
FT   STRAND          582..585
FT                   /evidence="ECO:0007744|PDB:1CDZ"
FT   HELIX           592..598
FT                   /evidence="ECO:0007744|PDB:1CDZ"
FT   STRAND          605..607
FT                   /evidence="ECO:0007744|PDB:1CDZ"
FT   HELIX           610..616
FT                   /evidence="ECO:0007744|PDB:1CDZ"
FT   TURN            617..619
FT                   /evidence="ECO:0007744|PDB:1CDZ"
FT   HELIX           624..627
FT                   /evidence="ECO:0007744|PDB:1CDZ"
SQ   SEQUENCE   633 AA;  69477 MW;  30DB3321234DBFC2 CRC64;
     MPEIRLRHVV SCSSQDSTHC AENLLKADTY RKWRAAKAGE KTISVVLQLE KEEQIHSVDI
     GNDGSAFVEV LVGSSAGGAG EQDYEVLLVT SSFMSPSESR SGSNPNRVRM FGPDKLVRAA
     AEKRWDRVKI VCSQPYSKDS PFGLSFVRFH SPPDKDEAEA PSQKVTVTKL GQFRVKEEDE
     SANSLRPGAL FFSRINKTSP VTASDPAGPS YAAATLQASS AASSASPVSR AIGSTSKPQE
     SPKGKRKLDL NQEEKKTPSK PPAQLSPSVP KRPKLPAPTR TPATAPVPAR AQGAVTGKPR
     GEGTEPRRPR AGPEELGKIL QGVVVVLSGF QNPFRSELRD KALELGAKYR PDWTRDSTHL
     ICAFANTPKY SQVLGLGGRI VRKEWVLDCH RMRRRLPSRR YLMAGPGSSS EEDEASHSGG
     SGDEAPKLPQ KQPQTKTKPT QAAGPSSPQK PPTPEETKAA SPVLQEDIDI EGVQSEGQDN
     GAEDSGDTED ELRRVAEQKE HRLPPGQEEN GEDPYAGSTD ENTDSEEHQE PPDLPVPELP
     DFFQGKHFFL YGEFPGDERR KLIRYVTAFN GELEDNMSDR VQFVITAQEW DPSFEEALMD
     NPSLAFVRPR WIYSCNEKQK LLPHQLYGVV PQA
//
